Skip to content

Research at St Andrews

The role of moxifloxacin in tuberculosis therapy

Research output: Contribution to journalArticle

Abstract

Tuberculosis (TB) remains a global threat with more than 9 million new infections. Treatment remains difficult and there has been no change in the duration of the standard regimen since the early 1980s. Moreover, many patients are unable to tolerate this treatment and discontinue therapy, increasing the risk of resistance. There is a growing tide of multidrug resistance and few effective antibiotics to tackle the problem. Since the turn of the millennium there has been a surge in interest in developing new therapies for TB and a number of new drugs have been developed. In this review the repurposing of moxifloxacin, an 8-methoxy-fluoroquinolone, for TB treatment is discussed. The evidence that underpins the development of this agent is reviewed. The results of the recently completed phase III trials are summarised and the reasons for the unexpected outcome are explored. Finally, the design of new trials that incorporate moxifloxacin, and that address both susceptible disease and multidrug resistance, is described.

Close

Details

Original languageEnglish
Pages (from-to)19-28
Number of pages10
JournalEuropean Respiratory Review
Volume25
Issue number139
DOIs
StatePublished - Mar 2016

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Centrifugation and decontamination procedures selectively impair recovery of important populations in Mycobacterium smegmatis

    Kennedy, J. A., Baron, V. O., Hammond, R. J. H., Sloan, D. J. & Gillespie, S. H. 1 Aug 2018 In : Tuberculosis.

    Research output: Contribution to journalArticle

  2. Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

    Tweed, C. D., Crook, A. M., Amukoye, E. I., Dawson, R., Diacon, A. H., Hanekom, M., McHugh, T. D., Mendel, C. M., Meredith, S. K., Murphy, M. E., Murthy, S. E., Nunn, A. J., Phillips, P. P. J., Singh, K. P., Spigelman, M., Wills, G. H. & Gillespie, S. H. 11 Jul 2018 In : BMC Infectious Diseases. 18, 11 p., 317

    Research output: Contribution to journalArticle

  3. Moxifloxacin replacement in contemporary tuberculosis drug regimens is ineffective against persistent Mycobacterium tuberculosis: in the Cornell mouse model

    Liu, Y., Pertinez, H., Davies, G. R., Gillespie, S. H., Coates, A. R. & Hu, Y. Jul 2018 In : Antimicrobial Agents and Chemotherapy. 62, 7, 9 p., e00190-18

    Research output: Contribution to journalArticle

  4. Forecasting clinical dose-response from pre-clinical studies in tuberculosis research - translational predictions with rifampicin

    Wicha, S. G., Clewe, O., Svensson, R. J., Gillespie, S. H., Hu, Y., Coates, A. R. M. & Simonsson, U. S. H. 19 Jun 2018 In : Clinical Pharmacology & Therapeutics. Early View

    Research output: Contribution to journalArticle

  5. The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis

    Svensson, E. M., Svensson, R. J., Te Brake, L. H. M., Boeree, M. J., Heinrich, N., Konsten, S., Churchyard, G., Dawson, R., Diacon, A. H., Kibiki, G. S., Minja, L. T., Ntingiya, N. E., Sanne, I., Gillespie, S. H., Hoelscher, M., Phillips, P. P. J., Simonsson, U. S. H. & Aarnoutse, R. 18 Jun 2018 In : Clinical Infectious Diseases. 67, 1, p. 34-41 8 p.

    Research output: Contribution to journalArticle

ID: 241406887